- 09/23/2020
- eisai and merck present first-time data from two studies evaluating keytruda® (pembrolizumab) plus lenvima® (lenvatinib) in seven different tumor types at esmo virtual congress 2020
- 09/20/2020
- eisai china inc. successfully held "2020 ads summit"
- 09/18/2020
- eisai presents latest data of phase i clinical trial on liposomal formulation of anti-cancer agent halaven® (eribulin) at esmo virtual congress 2020
- 09/11/2020
- eisai to present abstracts on oncology products and pipeline at esmo virtual congress 2020
- 09/07/2020
- eisai to take over manufacturing and marketing approval for equfina® 50mg tablets (safinamide mesilate) in japan from meiji seika pharma
- 09/02/2020
- eisai china wins "greater suzhou best employer" award for four consecutive years
- 09/01/2020
- promote development of core philosophy of eisai – the second hhc summit of eisai china
- 08/30/2020
- eisai china shortlisted for top 100 pharmaceutical enterprises in china for five consecutive years
- 08/25/2020
- relieving discomfort caused by dry skin with the moisturizing effect of pharmaceutical care products eisai to launch sahne® medical spray and sahne® medical cream
- 08/25/2020
- eisai to present latest data of lemborexant at 34th annual sleep meeting (sleep2020)
